Get informed about the latest news in development and production of Human Milk Oligosaccharides (HMOs). We are inventor of a specific fermentation process and the first to produce Human Milk Oligosaccharides on an industrial scale.

Jennewein Biotechnologie will be present as an exibitor at different fairs:

Listen to several interviews and get informed by experts about the importance of breastfeeding, the major role HMOs play especially for newborns and the impact of HMOs on norovirus infections.

  • Prototype of „My baby’s microbiome“ analysis-kit
  • A sample of our HMOs for your daily nutritional intake
  • The role that HMOs play in your microbiome


Date Name of the fair Location
05.- 06.02.2019 Euroforum Frankfurt
12.02.2019 SCIECON Berlin
06.- 07.03.2019 Mikrobiom Kongress Taiwan
09.- 10.04.2019 Biotechnologietage Würzburg
16.- 19.04.2019 Microbiome Conference Boston
07.05.2019 Swiss Biotech Day 2019 Basel
05. -08.06.2019 ESPGHAN Glasgow
24. -26.07.2019 CBME Shanghai
10. -12.10.2019 XPOMET Berlin
16. -19.10.2019 NASPHGHAN Chicago
05. -07.11.2019 CPHL Europe Frankfurt
31. -10.11.2019 World of Microbiome Mailand
03. -05.12.2019 FI Europe Paris
25. -26.09.2019 Vitafoods Asia Singapur
31.10. -02.11.2019 World of Microbiome Mailand

If you want to visit us there, please do not hesitate to contact us:
Discover who we are and how we follow up on our vision.
Explore our unique portfolio and see how babies can benefit from our products.
Jennewein Biotechnologie manufactures rare functional sugars for a wide range of applications, including nutritional, pharmaceutical and cosmetic products – and takes a leading position in the market of rare monosaccharides and complex oligosaccharides.

We produce rare monosaccharides such as L-fucose and sialic acid and provide an extensive portfolio of HMOs. In particular 2'- fucosyllactose and 3'- fucosyllactose.

From the very beginning, we have focused on human milk oligosaccharides (HMOs). Although HMOs occur naturally in human milk, economical processes for the large-scale production of food-grade HMOs were not available when we launched the company in 2005. We set out to produce these molecules in very large quantities at a low cost and to manufacture food-grade quality products for use as functional food ingredients in infant formula.

During the last decade we have become a technology driver and we now partner well-known brands and international companies for the development and production of HMOs for the nutrition industry, as well as medical and scientific applications.

“In everything we do we try to close the gap between human breast milk and infant formula. And we're getting closer year by year!”
Stefan Jennewein, Founder & CEO of Jennewein Biotechnologie GmbH
Human milk oligosaccharides (HMOs) are complex sugars that are only found in human breast milk. Because we are constantly striving for our vision, babies fed on formula milk are now able to benefit from the unique properties of HMOs, which had not been possible up to now.1
These benefits include for example:
  • The prebiotic effect which is responsible for the nourishing of the beneficial microbes in the microbiome and thus providing a growth advantage over less beneficial bacteria2,3
  • Reducing the risk of developing non-communicable diseases because scientists see a linkage between many chronic diseases - such as allergies, irritable bowel syndrome obesity - and the microbiome4
  • The Anti-adhesive effect
  • Supporting early brain development, language skills as well as memory, normal social and cognitive behaviours.
In addition to our first food-grade HMO (2'-fucosyllactose) we currently have five other HMOs in the registration process. Towards the end of 2018, we intend to commence the large-scale production of lacto-N-neo-tetraose. We recently initiated the first clinical trial with a mixture of HMOs emulating the profile found in human milk. In addition to HMOs, we also provide the simpler sugars L-fucose and sialic acid, which are present in human milk in significant quantities.

Pioneers win

Get in touch!

Thank you for your interest in Jennewein Biotechnologie!

If you would like to visit us at our booth, please don’t hesitate to contact us:

Bode L (2012) Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology 22, 1147-1162
Biagi E et al. (2017) The bacterial ecosystem of mother’s milk and infant’s mouth and gut. Front Microbiol 8, 1214
Zivkovic AM et al. (2010) Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci USA 108, 4653-4658
Hickey R (2012) The role of oligosaccharides from human milk and other sources in prevention of pathogen adhesion. Intl Dairy Journal 22, 141-146